Payment overview · 2025
General Payments
$664.10
31 reported records · 11 companies
Healthcare provider profile · identity verified
Martha C Combs-Woolum, MD
Allopathic & Osteopathic Physicians|General Practice · PINEVILLE, KY · NPI 1033121017
Verified facts
What the public records show
CMS Open Payments records show Martha C Combs-Woolum, MD received $664.10 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.78 | 21.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.16 | 16.4% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $75.13 | 11.3% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $65.97 | 9.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.00 | 8.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.35 | 7.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.90 | 6.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.17 | 6.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.35 | 4.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.66 | 4.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.63 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.10 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.48 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $109.16 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $75.13 | 4 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $65.97 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.00 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $42.17 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 268 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
215 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
268 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1188 | 274 |
| Atorvastatin Calcium | Atorvastatin Calcium | 865 | 218 |
| Pantoprazole Sodium | Pantoprazole Sodium | 832 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 740 | 182 |
| Valsartan | Valsartan | 724 | 169 |
| Gabapentin | Gabapentin | 654 | 131 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 572 | 170 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 142 |
| Losartan Potassium | Losartan Potassium | 481 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 425 | 108 |
| Montelukast Sodium | Montelukast Sodium | 399 | 115 |
| Azithromycin | Azithromycin | 383 | 261 |
| Furosemide | Furosemide | 362 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 357 | 89 |
| Famotidine | Famotidine | 352 | 84 |
| Meloxicam | Meloxicam | 352 | 99 |
| Tramadol Hcl | Tramadol Hcl | 341 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 340 | 99 |
| Sertraline Hcl | Sertraline Hcl | 309 | 68 |
| Lisinopril | Lisinopril | 306 | 78 |
| Omeprazole | Omeprazole | 303 | 77 |
| Buspirone Hcl | Buspirone Hcl | 282 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 70 |
| Eliquis | Apixaban | 268 | 61 |
| Potassium Chloride | Potassium Chloride | 258 | 75 |
| Metformin Hcl | Metformin Hcl | 248 | 65 |
| Metformin Hcl Er | Metformin Hcl | 246 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 242 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 54 |
| Simvastatin | Simvastatin | 220 | 51 |
| Synthroid | Levothyroxine Sodium | 215 | 49 |
| Trazodone Hcl | Trazodone Hcl | 207 | 47 |
| Ondansetron Hcl | Ondansetron Hcl | 203 | 73 |
| Allopurinol | Allopurinol | 202 | 46 |
| Ezetimibe | Ezetimibe | 202 | 44 |
| Carvedilol | Carvedilol | 174 | 46 |
| Ozempic | Semaglutide | 171 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 170 | 24 |
| Mounjaro | Tirzepatide | 165 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 164 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 47 |
| Glimepiride | Glimepiride | 154 | 44 |
| Pregabalin | Pregabalin | 153 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 151 | 39 |
| Clonazepam | Clonazepam | 140 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 139 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 62 |
| Januvia | Sitagliptin Phosphate | 136 | 28 |
| Cefdinir | Cefdinir | 134 | 104 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 133 | 98 |
| Bumetanide | Bumetanide | 132 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 58 |
| Nitroglycerin | Nitroglycerin | 130 | 51 |
| Ibuprofen | Ibuprofen | 129 | 39 |
| Alprazolam | Alprazolam | 128 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 27 |
| Atenolol | Atenolol | 119 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 30 |
| Lorazepam | Lorazepam | 115 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 32 |
| Irbesartan | Irbesartan | 111 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 110 | 82 |
| Methylprednisolone | Methylprednisolone | 105 | 88 |
| Meclizine Hcl | Meclizine Hcl | 104 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 102 | 82 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 101 | 28 |
| Clonidine Hcl | Clonidine Hcl | 98 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 98 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 28 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 91 | 20 |
| Xarelto | Rivaroxaban | 90 | 29 |
| Farxiga | Dapagliflozin Propanediol | 89 | 16 |
| Linzess | Linaclotide | 87 | 36 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 87 | 22 |
| Celecoxib | Celecoxib | 86 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 79 | 17 |
| Bupropion Xl | Bupropion Hcl | 78 | 19 |
| Fluconazole | Fluconazole | 78 | 53 |
| Chlorthalidone | Chlorthalidone | 75 | 24 |
| Spironolactone | Spironolactone | 75 | 17 |
| Donepezil Hcl | Donepezil Hcl | 74 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 74 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 73 | 12 |
| Glipizide | Glipizide | 73 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 73 | 18 |
| Nystatin | Nystatin | 71 | 51 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 19 |
| Kerendia | Finerenone | 70 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 70 | 20 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 63 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 21 |
| Jardiance | Empagliflozin | 63 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 15 |
| Alendronate Sodium | Alendronate Sodium | 61 | 17 |
| Ondansetron Odt | Ondansetron | 59 | 37 |
| Propranolol Hcl | Propranolol Hcl | 58 | 17 |
| Trintellix | Vortioxetine Hydrobromide | 58 | suppressed |
| Cephalexin | Cephalexin | 57 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 11 |
| Vascepa | Icosapent Ethyl | 57 | 12 |
| Glipizide Er | Glipizide | 56 | suppressed |
| Lansoprazole | Lansoprazole | 55 | 13 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Sucralfate | Sucralfate | 54 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 15 |
| Novolog Flexpen | Insulin Aspart | 53 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | 18 |
| Prednisone | Prednisone | 50 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 40 |
| Entresto | Sacubitril/Valsartan | 49 | 15 |
| Promethazine Hcl | Promethazine Hcl | 48 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 12 |
| Finasteride | Finasteride | 46 | 13 |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Clotrimazole | Clotrimazole | 40 | 14 |
| Rivastigmine | Rivastigmine | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Premarin | Estrogens, Conjugated | 39 | 14 |
| Baclofen | Baclofen | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 11 |
| Estradiol | Estradiol | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 17 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 35 | 29 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Colchicine | Colchicine | 31 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Felodipine Er | Felodipine | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 20 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Veozah | Fezolinetant | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | 13 |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 16 |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Nystop | Nystatin | 15 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Repatha Pushtronex | Evolocumab | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Zolmitriptan | Zolmitriptan | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clarithromycin | Clarithromycin | 13 | 12 |
| Famciclovir | Famciclovir | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.10 · 31 records | Novo Nordisk Inc | Auvelity, ELIQUIS, GVOKE HYPOPEN, IBSRELA, JOURNAVX, Kerendia, Ozempic, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error